BWA
FDMT icon

Basecamp Wealth Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Basecamp Wealth Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479 Sell
36
-109
-75% -$1.06K ﹤0.01% 1641
2026
Q1 		$1.35K Hold
145
– – ﹤0.01% 1491
2025
Q4 		$1.09K Buy
+145
New +$1.47K ﹤0.01% 1477

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Basecamp Wealth Advisors's FDMT Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its 4D Molecular Therapeutics (FDMT) stake by 75% in Q2 2026, selling an estimated $1.06K and leaving 36 shares worth $479. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

Basecamp Wealth Advisors first reported a position in FDMT in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.35K in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Basecamp Wealth Advisors held 36 shares of 4D Molecular Therapeutics worth $479 as of Q2 2026.
  • Basecamp Wealth Advisors sold 109 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.06K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1641 holding.
  • Basecamp Wealth Advisors first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's 4D Molecular Therapeutics position peaked at $1.35K in Q1 2026.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.